LIXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lixte Biotechnology Holdings Inc (LIXT) is not a strong buy for a long-term beginner investor at this time. The lack of significant trading trends, absence of positive news or catalysts, and weak financial performance do not support an immediate investment decision. While technical indicators show some positive momentum, these are insufficient to justify a buy for a long-term strategy.
The MACD is positive and expanding (0.0271), indicating bullish momentum. RSI is at 71.417, which is in the neutral zone. Moving averages are converging, suggesting indecision in the market. Key resistance levels are at R1: 3.173 and R2: 3.343, with support at S1: 2.623 and S2: 2.453. The stock has a 90% chance to increase by 0.35% in the next day, 2.08% in the next week, and 1.42% in the next month.
NULL identified. There is no recent news, and hedge funds and insiders are neutral with no significant trading trends.
The company's financial performance is weak with no revenue growth, a negative net income of -$2,562,600 (despite improvement YoY), and no gross margin. Additionally, there are no recent congress trades or influential figure activity.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY but is still negative at -$2,562,600. EPS improved to -0.32 (up 18.52% YoY), but overall financials remain weak.
No analyst rating or price target data available.
